BioSpace News Archive

Veteran owned Carolina Liquid Chemistries Corp. (CLC) announced it has teamed up with New Jersey-based Alltests Clinical Solutions, LLC (Alltests), an authorized distributor, to distribute the Flowflex COVID-19 Antigen Home Test.

Increasing adoption of robust disinfectants and sanitizers to clean critical medical devices, rising number of surgical procedures performed across the globe, and implementation of cleanliness protocols in healthcare settings are some key factors expected to drive market growth.

Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals for the development, registration, supply, commercialization and distribution of cenobamate on an exclusive basis in Canada.

Henry Schein to Present at the 40th Annual J.P. Morgan Healthcare Investor Conference.

Cyclacel Pharmaceuticals, Inc. today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022.

Taysha Gene Therapies, Inc. today announced that it has been added to the ICE Biotechnology Index (NYSE:ICEBIO) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021.

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator and exporter, reports results for its year and fourth quarter ended September 30, 2021 (“ 2021 ” and “ Q4 ”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from medical devices.

The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that Mr. Roderic W. Lewis notified the Board of Directors (the “Board”) that he intends to retire as a director of the company effective December 31, 2021.

CEO Gerald Commissiong is also scheduled to appear on BNC at 1:50PM EST to discuss the authorization of Pfizer’s COVID antiviral drug & Tollovir™ Phase 2 for hospitalized COVID.

Arcutis Biotherapeutics, Inc. today announced that it has obtained a $225 million term loan facility from funds managed by SLR Capital Partners (“SLR”).